Deepwise AI Secures $60M Funding to Advance AI-Powered Drug Development

AI-powered pharmaceutical company Deepwise AI recently secured $60 million in new funding, bringing its total funding to over $100 million in just two months. The funding round included investments from Xinchen Capital, Jinyi Capital, and Kaitai Capital, with continued investment from CDH Baifu and Xinding Capital. Exponent Capital served as the exclusive financial advisor.

AI Revolutionizing Drug Development

Deepwise AI distinguishes itself from many companies currently applying AI to the pharmaceutical industry by offering comprehensive solutions across the entire drug development lifecycle. While many are limited to the preclinical phase, Deepwise AI provides intelligent solutions from preclinical research through to post-market research, including regulatory submissions and clinical trials.

Did You Know? Deepwise AI’s AI-generated clinical study protocols have achieved “zero corrections” and were approved by regulatory authorities in previous collaborations.

A New Approach to AI in Pharma

The company has moved beyond simply replacing individual functions in the drug development process. Deepwise AI has developed what it calls a “bionic brain” comprised of thousands of “atomic agents” – including Protocol Agents for study design, Statistical Agents for calculations, and Regulatory Agents for compliance – that work collaboratively. This system mimics human thought processes, reflecting, learning, and improving over time.

Deepwise AI’s technology addresses the issue of “hallucinations” in AI models, a critical concern in medical applications, through a four-layered protection system encompassing training, inference, cross-checking, and post-processing. This has reportedly improved the industrial accuracy of its AI to 99.9%.

Protocol Rehearsal: A Potential Game Changer

Deepwise AI has introduced a new “Protocol Rehearsal” agent that conducts “virtual clinical studies” using AI to simulate potential outcomes before human trials begin. This could accelerate the implementation of AI in clinical studies and shift drug development from a labour-intensive process to one driven by intelligent decision-making.

Expert Insight: The investment in Deepwise AI signals a potential shift in the pharmaceutical industry, moving beyond valuing only pipeline assets to recognizing the transformative potential of underlying technology platforms. This could lead to increased investment in AI-driven drug development solutions.

Investor Perspectives

Zhao Lei, a partner at Xinchen Capital, believes AI will structurally advance clinical contract research organizations (CROs) in the long term. Li Hui, founder and managing partner of Jinyi Capital, stated that AI is driving a new productivity revolution globally and that Deepwise AI is positioned to accelerate drug development and reduce costs. Zhao Tianjun, Vice President of Kaitai Capital, emphasized that AI is “the medium of the future” and that Deepwise AI is fundamentally changing the decision-making and execution models of clinical trials.

Frequently Asked Questions

What is Deepwise AI’s core technology?

Deepwise AI has developed a “bionic brain” comprised of thousands of “atomic agents” that work collaboratively to mimic human thought processes and improve efficiency in clinical trials.

How much funding has Deepwise AI received recently?

Deepwise AI recently secured $60 million in new funding, following a $50 million funding round in December, bringing its total funding to over $100 million in two months.

What is the Protocol Rehearsal agent?

The Protocol Rehearsal agent conducts “virtual clinical studies” using AI to simulate potential outcomes before human trials begin, potentially accelerating the drug development process.

As AI continues to evolve, how might companies like Deepwise AI reshape the future of pharmaceutical research and development?